The development of effective malaria vaccines remains a global health priority. Currently, 31 the most advanced vaccine, known as RTS,S, has only shown modest efficacy in clinical 32 trials. Thus, the development of more efficacious vaccines by improving the formulation of 33 RTS,S for increased efficacy or to interrupt malaria transmission are urgently needed. The 34 RTS,S vaccine is based on the presentation of a fragment of the sporozoite antigen on the 35 surface of virus-like particles (VLPs) based on human hepatitis B virus (HBV). In this study, 36 we have developed and evaluated a novel VLP platform based on duck HBV (known as 37 Metavax) for malaria vaccine development. This platform can incorporate large and complex 38 proteins into VLPs and is produced in a Hansenula cell line compatible with cGMP vaccine 39 production. Here, we have established the expression of several leading P. falciparum 40 malaria vaccine candidates as VLPs. This includes Pfs230 and Pfs25, which are candidate 41 transmission-blocking vaccine antigens. We demonstrated that the VLPs effectively induce 42 antibodies to malaria vaccine candidates with minimal induction of antibodies to the duck-43 HBV scaffold antigen. Antibodies to Pfs230 also recognised native protein on the surface of 44 gametocytes, and antibodies to both Pfs230 and Pfs25 demonstrated transmission-reducing 45 activity in standard membrane feeding assays. These results establish the potential utility of 46
INTRODUCTION
were co-expressed with a gene encoding the wildtype dS (Genbank ref: MF510122) in a 144 recombinant Hansenula-derived yeast cell line. The purification of the chimeric VLPs was 145 based on a downstream process approved for human VLP vaccine production from yeast 146 [26] including adaptations for the purification of VLPs containing the P. falciparum antigens 147 [25] . The relative incorporation of the Pfs230-dS/dS or Pfs25-dS/dS fusion proteins into 148 VLPs, compared to total protein, was estimated by densitometry analysis of Coomassie 149 stained gels of VLPs, as described in the accompanying manuscript [25] . The relative 150 incorporation rates were ~30% for Pfs230c-dS/dS VLPs, ~24% for Pfs230D1M-dS/dS VLPs, 151 and ~3% for Pfs25-dS/dS VLPs. The expression of monomeric recombinant Pfs230D1M was performed in HEK293F cells as 155 previously described [27] . Briefly, a truncated form of Pfs230 containing the first 6-cys 156 domain of Pfs230 has previously been expressed as a monomeric recombinant protein in P. 7 or Pfs25). Secondary HRP-conjugated antibodies (polyclonal goat anti-mouse IgG at 1/1000 subsequently stopped using 1% SDS (for ABTS) or 1M sulphuric acid (for TMB). PBS was 172 used as a negative control and plates were washed thrice using PBS with 0.05% Tween in 173 between antibody incubation steps. The level of antibody binding was measured as optical 174 density at 405nm (for ABTS) or 450nm (for TMB).
(1/500) with ethidium bromide to distinguish between infected and uninfected erythrocytes
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(1/1000), with washing between each step. Data was acquired by flow cytometry (FACS 183 Verse, BD Biosciences) and analysed using FlowJo software. Antibody levels are expressed 184 as the geometric mean fluorescence intensity (MFI; arbitrary units).
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Immunofluorescence Microscopy
187
Thin blood smears of stage V 3D7 gametocyte-infected erythrocytes were fixed in 90% 188 acetone and 10% methanol for 5 min at -20C as previously described [30] . Briefly, slides 189 were rehydrated in PBS and blocked with 6% BSA for 30 minutes before incubation with 190 primary antibodies (rabbit antibodies were tested at 1/100) for 2h. Slides were subsequently 191 incubated with the secondary AlexaFluor 488-conjugated IgG (1/1000; Thermo Scientific) for 192 1h. Slides were washed thrice in PBS between antibody incubation steps. Slides were 193 mounted in medium containing DAPI to label the parasite nucleus. Images were collected the shaker for 5 min prior to immunisations. New Zealand White rabbits were immunised 2 202 weeks apart with 3 doses of chimeric VLPs. The total amount of protein and adjuvant used 203 in each immunisation is presented in Supplementary Tables S1-S3 
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Animal immunisations were approved by the Animal Ethics Committee of the Walter and
Measuring transmission-blocking activity by standard membrane feeding assays 218
IgG purification from individual rabbit serum samples was performed using Protein G 219 columns (GE Healthcare) according to the manufacturer instructions and adjusted to a final 220 concentration of 20 mg/ml in PBS. The standardized methodology for performing the 221 standard membrane feeding assays (SMFA) was described previously [31] . Briefly, 16-18 immediately fed to ~50 female Anopheles stephensi mosquitoes through a membrane-225 feeding apparatus. Mosquitoes were kept for 8 days and dissected to enumerate the oocysts 226 in the midgut (n=40 per group for the negative control group, and n=20 for test groups). As 227 the negative controls, total IgG purified from pre-immune rabbit sera were utilised. Only includes the first two 6-cysteine domains of Pfs230 [23] , was used to generate fusion using different platforms in published studies and has advanced into clinical trials [11, 13] . We evaluated whether rabbit antibodies generated against Pfs230c-dS/dS and Pfs230D1M-287 dS/dS VLPs were capable of recognizing native antigens expressed on the surface of 288 mature stage V gametocytes by flow cytometry ( Fig 3A) . The majority of the rabbit sera had 289 substantial antibody reactivity to the surface of mature gametocytes, suggesting that 290 vaccine-induced antibodies recognize native Pfs230 ( Fig 3A) . This finding was confirmed 291 using immunofluorescence microscopy, which showed that rabbit antibodies generated 292 against Pfs230c-dS/dS VLPs labelled native Pfs230 expressed on the surface of fixed 293 mature gametocytes ( Fig 3B) .
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Rabbit antibodies induced by chimeric VLPs have transmission-reducing activity
296
To address the functional significance of rabbit antibodies generated against sexual-stage 297 chimeric VLPs, we examined the ability of these antibodies to inhibit mosquito infection 298 through standard membrane feeding assays (SMFA) in the presence of human complement 299 [31] . Functional transmission-blocking activity is defined as the reduction in oocyst count 300 compared to a negative control group. When antibodies against Pfs230c-dS/dS VLPs were 301 tested at 7.5mg/ml, none of them showed significant inhibition ( 
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Our immunogenicity studies showed that the chimeric VLPs could elicit an immune response 340 in rabbits. For immunisations with Pfs230c-dS/dS VLP, two dosing regimens were used in 341 the presence and absence of Alhydrogel. As the higher dose appeared to induce a better 342 antibody response in rabbits, and formulation with Alhydrogel was needed for high antibody 343 levels, immunisations with Pfs230D1M-dS/dS VLP were done at a single dose (using the 
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While further studies with larger numbers of animals, and including mice or rats, will be 369 required to better understand variability in vaccine responses, the findings here are sufficient 370 to establish a proof-of-concept for generating transmission-blocking activity using VLPs. Of 371 note, transmission-reducing activity was not observed for antibodies generated against functional epitopes were not displayed, or important antibody-binding epitopes were 374 masked. These factors potentially resulted in low purity and reduced yield of chimeric VLP 375 and thus led to the lack of functional antibodies generated.
377
In conclusion, we have demonstrated the successful display of sexual-stage antigens 378 Pfs230 and Pfs25 on the surface of chimeric VLPs. We have established a proof-of-concept 379 which showed that these VLPs generated significant immune responses that recognised 380 homologous recombinant protein and native sexual-stage antigens expressed on 381 gametocytes. Further, these antibodies had the ability to block the transmission of parasites 382 to mosquitoes through membrane feeding assays. Together, our results support the further 383 evaluation of chimeric VLPs as a novel delivery platform for leading malaria vaccine 
